Table S2.
Chemotherapy codes and emetogenic potential
| Description | GPI code | HCPCS code | Emetogenicity | Formulation |
|---|---|---|---|---|
| Carmustine | 21102010x | J9050, C9437 | Other | IV |
| Cisplatin | 211000200020x | J9060, J9062, C9418 | Other | IV |
| Dacarbazine | 2170002000x | J9130, J9140, C9423 | HEC | IV |
| Mechlorethamine | 211010301021x | J9230 | HEC | IV |
| Streptozotocin | 21102030002105 | J9320 | HEC | IV |
| Alemtuzumab | 21353010x | J9010 | Minimal | IV |
| Arsenic trioxide | 21700008x | J9017 | MEC | IV |
| Azacitidine | 21300003x | J9025 | MEC | IV |
| Bendamustine | 21100009x | J9033 | MEC | IV |
| Carboplatin | 21100015x | J9045 | MEC | IV |
| Clofarabine | 21300008x | J9027, C9129 | MEC | IV |
| Dactinomycin | 212000200021x | J9120 | MEC | IV |
| Daunorubicin | 21200030x | J9150–J9151, C9424 | MEC | IV |
| Doxorubicin | 21200040x | J9000–J9001, C9415 | Other | IV |
| Epirubicin | 21200042x | J9178, J9180 | Other | IV |
| Idarubicin | 21200045x | J9211, C9429 | MEC | IV |
| Ifosfamide | 2110102500x, 219900024064x | J9208, C9427 | Other | IV |
| Irinotecan | 21550040x | J9206 | MEC | IV |
| Melphalan | 211010400021x, 211010401021x | J9245 | MEC | IV |
| Oxaliplatin | 21100028x | J9263, C9205 | MEC | IV |
| Temozolomide | 211040700021x | J9328, C9253 | MEC | IV |
| Aldesleukin | 21703020x | J9015 | Other | IV |
| Amifostine crystalline | 21758010x | J0207 | Other | IV |
| Cyclophosphamide | 21101020002x | J9070–J9097, C9420, C9421 | Other | IV |
| Cytarabine | 21300010x | J9098–J9110, C9422 | Other | IV |
| Interferon-α | 217000601x, 217000602x, 217000603x | J9212–J9215 | Other | IV |
| Altretamine | 21100005x | MEC/HEC | Oral | |
| Procarbazine | 21700050x | S0182 | MEC/HEC | Oral |
| Cyclophosphamide | 211010200003x | J8530 | Other | Oral |
| Imatinib | 21534035x | S0088 | Minimal/Low | Oral |
| Temozolomide | 211040700001x | J8700 | Other | Oral |
| Busulfan | 211000100003x | J0594, J8510 | Other | Oral |
| Estramustine phosphate sodium | 2140302010x | MEC/HEC | Oral | |
| Etoposide | 21500010x | J8560 | MEC/HEC | Oral |
| Lomustine | 211020200001x | S0178 | MEC/HEC | Oral |
Notes: Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis, Version 1.2012. © National Comprehensive Cancer Network, Inc 2015. All rights reserved. Accessed August 11, 2011. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. Other = NCCN emetogenicity rating depends on dosage.
Abbreviations: GPI, generic product identifier; HCPCS, Healthcare Common Procedure Coding System; HEC, highly EC; MEC, moderately EC; EC, emetogenic chemotherapy; IV, intravenous.